GO:0072521 purine-containing compound metabolic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072521 describes the chemical reactions and pathways involving any purine-containing compound, including purine nucleotides, nucleosides, and their derivatives.
• Purine metabolism is essential for DNA/RNA synthesis, energy transfer, and cellular signaling, and its dysregulation is linked to cancer, neurological disorders, and parasitic infections.
• Key enzymes such as ADA, GART, and IMPDH are frequently studied using CRISPR knockout and point-mutation models to dissect their roles in disease.
• Proteomic and acetylome profiling studies have revealed that purine metabolic enzymes are dynamically regulated during aging and in response to environmental factors.
• Comparative proteomics across species highlights conserved and divergent features of purine metabolism, informing drug target discovery.
• CRISPR-based screens and bioinformatics are powerful tools to identify novel regulators of purine metabolism and to validate candidate genes in relevant disease models.
Description
Purine-containing compound metabolic process (GO:0072521) encompasses the chemical reactions and pathways involving any compound that contains purine or a formal derivative thereof. This includes the biosynthesis, interconversion, and degradation of purine nucleotides (AMP, GMP, IMP), nucleosides (adenosine, guanosine), and related molecules such as inosine and uric acid. These processes are fundamental to all living organisms, providing the building blocks for nucleic acids, energy carriers (ATP, GTP), and signaling molecules (cAMP, cGMP). Dysregulation of purine metabolism is implicated in a wide range of human diseases, including cancer, immunodeficiency, neurological disorders, and parasitic infections. For researchers, understanding the enzymes and regulatory mechanisms of this pathway is critical for developing targeted therapies and diagnostic tools. Recent advances in proteomics and CRISPR-based gene editing have enabled systematic interrogation of purine metabolic networks in health and disease.
purine-containing compound metabolic process At A Glance
| GO ID | GO:0072521 |
|---|---|
| GO term | purine-containing compound metabolic process |
| Ontology | biological_process |
| Synonym | purine and derivative metabolic process; purine-containing compound metabolism |
| Major function | Biosynthesis, interconversion, and degradation of purine-containing compounds such as nucleotides, nucleosides, and bases |
| Key enzymes | ADA, GART, IMPDH, HPRT1, XDH, and many others |
| Associated diseases | Cancer, immunodeficiency, gout, neurological disorders, parasitic infections |
| Research methods | CRISPR knockout/knock-in, proteomics, metabolomics, enzyme assays |
What Is GO:0072521?
According to the Gene Ontology, GO:0072521 (purine-containing compound metabolic process) is defined as the chemical reactions and pathways involving a purine-containing compound, i.e. any compound that contains purine or a formal derivative thereof. This broad term covers the metabolism of purine bases (adenine, guanine), nucleosides (adenosine, guanosine), nucleotides (AMP, GMP, IMP), and their various derivatives, including cofactors and signaling molecules. It encompasses both anabolic (biosynthesis) and catabolic (degradation) routes, as well as salvage pathways that recycle purine bases.
Why Is purine-containing compound metabolic process Important in Cell Biology?
Purine-containing compound metabolic process is essential for life because it supplies the building blocks for DNA and RNA, provides energy currency (ATP, GTP), and generates signaling molecules that regulate cell growth, differentiation, and immune responses. Defects in purine metabolism cause severe human diseases, including adenosine deaminase deficiency (SCID), Lesch-Nyhan syndrome, and gout. Moreover, many pathogens rely on purine salvage pathways, making these enzymes attractive drug targets. Understanding the regulation of this pathway is therefore crucial for both basic biology and translational medicine.
• Provides precursors for nucleic acid synthesis, essential for cell proliferation and survival.
• Maintains cellular energy homeostasis through ATP and GTP production.
• Generates second messengers such as cAMP and cGMP for signal transduction.
• Dysregulation leads to cancer, as purine metabolism supports rapid tumor growth.
• Enzyme deficiencies cause immunodeficiency (ADA deficiency) and neurological disorders (Lesch-Nyhan syndrome).
• Pathogens like Plasmodium falciparum depend on purine salvage, making enzymes like ADA drug targets.
• Aging is associated with altered purine metabolism, as revealed by proteomic and acetylome profiling.
• Environmental factors and maternal atopy can influence epigenetic regulation of metabolic genes.
• Comparative proteomics across species identifies conserved and unique purine metabolic enzymes.
• CRISPR screens enable functional dissection of purine metabolic networks in disease models.
What Happens During purine-containing compound metabolic process?
De Novo Purine Biosynthesis
In simple terms: The cell builds purine rings from scratch using simple molecules.
De novo purine biosynthesis is a complex, energy-intensive pathway that converts phosphoribosyl pyrophosphate (PRPP) into inosine monophosphate (IMP) through a series of ten enzymatic steps. Key enzymes include GART, PFAS, and PAICS. This pathway is essential for rapidly dividing cells and is often upregulated in cancer. The process is tightly regulated by feedback inhibition from downstream nucleotides.
Salvage Pathways
In simple terms: The cell recycles purine bases from degraded nucleotides instead of making them from scratch.
Salvage pathways recover free purine bases (adenine, guanine, hypoxanthine) and convert them back into nucleotides. Key enzymes include HPRT1, APRT, and ADA. These pathways are more energy-efficient than de novo synthesis and are critical in tissues with limited capacity for de novo synthesis, such as the brain. Deficiencies in salvage enzymes cause severe disorders like Lesch-Nyhan syndrome.
Interconversion of Purine Nucleotides
In simple terms: The cell converts one type of purine nucleotide into another as needed.
Purine nucleotides can be interconverted to balance cellular pools. For example, IMP can be converted to AMP via adenylosuccinate synthase and lyase, or to GMP via IMP dehydrogenase and GMP synthase. These reactions are regulated by feedback inhibition and energy status. IMPDH is a target for immunosuppressive and antiviral drugs.
Catabolism and Uric Acid Production
In simple terms: The cell breaks down purines into uric acid for excretion.
Purine catabolism involves the sequential degradation of nucleotides to nucleosides, bases, and finally uric acid in humans. Key enzymes include ADA, PNP, and XDH. Overproduction or impaired excretion of uric acid leads to hyperuricemia and gout. In other organisms, further degradation to allantoin occurs.
Regulation by Feedback and Energy Status
In simple terms: The cell adjusts purine production based on its energy needs and available building blocks.
Purine metabolism is regulated at multiple levels, including feedback inhibition of committed steps by downstream nucleotides (e.g., AMP, GMP inhibiting PRPP amidotransferase), allosteric regulation, and transcriptional control. Energy status (ATP/ADP ratios) influences flux through the pathway. Dysregulation of these controls contributes to metabolic diseases and cancer.
Key Genes Involved in GO:0072521 purine-containing compound metabolic process
The following genes encode enzymes and regulators that are central to purine-containing compound metabolic process, with relevance to human disease and research models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADA | Adenosine deaminase; degrades adenosine to inosine | Deficiency causes SCID; target for leukemia and parasitic infections |
| GART | Phosphoribosylglycinamide formyltransferase; de novo purine synthesis | Upregulated in cancer; potential drug target |
| IMPDH1/2 | Inosine monophosphate dehydrogenase; converts IMP to XMP | Target for immunosuppressants and antivirals; linked to retinitis pigmentosa |
| HPRT1 | Hypoxanthine phosphoribosyltransferase; salvage of hypoxanthine | Deficiency causes Lesch-Nyhan syndrome; used in HAT selection |
| XDH | Xanthine dehydrogenase/oxidase; produces uric acid | Inhibited by allopurinol for gout; role in oxidative stress |
| APRT | Adenine phosphoribosyltransferase; salvage of adenine | Deficiency causes 2,8-dihydroxyadenine urolithiasis |
| PNP | Purine nucleoside phosphorylase; degrades inosine and guanosine | Deficiency causes T-cell immunodeficiency |
| PFAS | Phosphoribosylformylglycinamidine synthase; de novo synthesis | Essential for purine synthesis; potential anticancer target |
| PAICS | Phosphoribosylaminoimidazole carboxylase; de novo synthesis | Overexpressed in cancers; involved in cell proliferation |
| ADSL | Adenylosuccinate lyase; converts SAICAR to AICAR and SAMP to AMP | Deficiency causes adenylosuccinate lyase deficiency with neurological symptoms |
| ATIC | 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase | Bifunctional enzyme in de novo purine synthesis; target in cancer |
| GUK1 | Guanylate kinase; converts GMP to GDP | Essential for GTP synthesis; potential antiviral target |
| NME1/2 | Nucleoside diphosphate kinases; synthesize nucleoside triphosphates | Involved in metastasis suppression and energy metabolism |
| ENTPD1 | Ectonucleoside triphosphate diphosphohydrolase 1; hydrolyzes ATP/ADP | Regulates extracellular purine signaling; role in immune response |
| NT5E | Ecto-5'-nucleotidase (CD73); converts AMP to adenosine | Immunosuppressive; target in cancer immunotherapy |
| ADORA2A | Adenosine A2A receptor; mediates adenosine signaling | Modulates inflammation and neurodegeneration; drug target |
| SLC29A1 | Equilibrative nucleoside transporter 1; uptake of nucleosides | Influences drug sensitivity; target for antiviral therapy |
| PPAT | Phosphoribosyl pyrophosphate amidotransferase; first step of de novo synthesis | Feedback regulated; overexpression in cancer |
How Is purine-containing compound metabolic process Regulated?
Purine-containing compound metabolic process is regulated at multiple levels. Feedback inhibition by end products (AMP, GMP) controls the committed step catalyzed by PPAT. Allosteric regulation and transcriptional control respond to energy status and growth signals. For example, mTOR signaling promotes purine synthesis to support cell growth. Additionally, epigenetic modifications such as DNA methylation can influence the expression of purine metabolic genes, as suggested by studies linking maternal atopy to offspring methylation signatures. Proteomic and acetylome profiling during aging have revealed dynamic changes in enzymes like ADA and GART, indicating that purine metabolism is subject to post-translational regulation.
purine-containing compound metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADA | Severe combined immunodeficiency (SCID) | Knockout mice, patient-derived iPSCs, CRISPR correction |
| HPRT1 | Lesch-Nyhan syndrome | HPRT1 knockout mice, neuronal cell models |
| IMPDH1 | Retinitis pigmentosa | Knock-in mice, retinal organoids |
| ADORA2A | Alzheimer's disease, inflammation | Knockout mice, AD animal models |
| XDH | Gout, hyperuricemia | XDH knockout mice, liver-specific models |
Purine Metabolism in Cancer
Many cancers exhibit upregulated de novo purine synthesis to support rapid proliferation. Enzymes such as GART, IMPDH, and ATIC are overexpressed in various tumors and are considered promising targets for chemotherapy. Inhibitors of IMPDH, such as mycophenolic acid, are used as immunosuppressants and have anticancer potential. CRISPR knockout of these enzymes in cancer cell lines can validate their essentiality and guide drug development.
Neurological Disorders and Purine Metabolism
Defects in purine salvage enzymes cause severe neurological disorders. Lesch-Nyhan syndrome, caused by HPRT1 deficiency, leads to self-injurious behavior and motor dysfunction. Adenylosuccinate lyase deficiency results in psychomotor retardation and epilepsy. Adenosine signaling, mediated by receptors like ADORA2A, is implicated in Alzheimer's disease and neuroprotection. Targeting purine metabolism may offer therapeutic avenues for these conditions.
Infectious Diseases and Parasitic Purine Salvage
Parasites like Plasmodium falciparum lack de novo purine synthesis and rely entirely on salvage pathways. Purine-containing carbonucleoside phosphonates have shown promise as novel chemotypes against P. falciparum. Similarly, other pathogens depend on purine salvage, making enzymes like ADA and PNP attractive drug targets. CRISPR-based editing of parasite genomes can help identify essential salvage genes.
Immunodeficiency and Autoimmunity
Adenosine deaminase (ADA) deficiency causes severe combined immunodeficiency (SCID) due to accumulation of toxic deoxyadenosine in lymphocytes. Purine nucleoside phosphorylase (PNP) deficiency leads to T-cell immunodeficiency. Conversely, adenosine signaling suppresses immune responses, and inhibitors of CD73 or adenosine receptors are being explored for cancer immunotherapy. These examples highlight the dual role of purine metabolism in immune regulation.
From purine-containing compound metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is ADA essential for lymphocyte survival? | ADA knockout cell lines (e.g., Jurkat) and mouse models |
| Does a point mutation in IMPDH1 cause retinal degeneration? | Knock-in mice expressing mutant IMPDH1 |
| Can overexpression of GART drive cancer proliferation? | Cancer cell lines with doxycycline-inducible GART overexpression |
| What is the role of ADORA2A in neuroprotection? | ADORA2A knockout mice in Alzheimer's models |
| How does purine metabolism change during aging? | Liver-specific knockout or tagged knock-in mice for metabolic enzymes |
| Which purine salvage genes are essential in Plasmodium? | CRISPR knockout in P. falciparum |
How to Study the purine-containing compound metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS metabolomics | Levels of purine nucleotides, nucleosides, bases | Quantify metabolic flux in cells and tissues |
| Enzyme activity assays | Catalytic activity of ADA, IMPDH, XDH, etc. | Validate CRISPR knockout or inhibitor effects |
| Proteomics | Protein expression and modifications | Identify dynamic changes during aging or disease |
| Acetylome profiling | Lysine acetylation sites on metabolic enzymes | Reveal post-translational regulation |
| CRISPR knockout screens | Gene essentiality and drug sensitivity | Discover novel purine metabolism regulators |
| RNA-seq | Transcriptional changes | Assess expression of purine metabolic genes |
| Methylation arrays | DNA methylation patterns | Link epigenetic regulation to purine metabolism |
| Comparative proteomics | Protein abundance across species | Identify conserved and unique enzymes |
Proteomics and Acetylome Profiling
Global proteomic and acetylome analyses have been used to quantify purine metabolic enzymes in tissues such as liver during aging. These methods reveal post-translational modifications that regulate enzyme activity. Comparative proteomics across species can identify conserved and unique features of purine metabolism.
Metabolomics and Enzyme Assays
Targeted metabolomics using LC-MS/MS allows quantification of purine nucleotides, nucleosides, and bases in cells and tissues. Enzyme activity assays for ADA, IMPDH, and XDH provide direct functional readouts. These methods are essential for validating CRISPR knockout phenotypes.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes required for purine metabolism under specific conditions, such as drug treatment or nutrient limitation. Hits can be validated with individual knockouts and rescue experiments. This approach is powerful for discovering new regulators and drug targets.
Epigenetic and Transcriptomic Analysis
RNA-seq and methylation arrays can reveal transcriptional and epigenetic regulation of purine metabolic genes. For example, maternal atopy has been associated with offspring DNA methylation changes in metabolic pathways. Integrating multi-omics data helps build regulatory networks.
How CRISPR Can Be Used to Study GO:0072521 purine-containing compound metabolic process
Knockout
CRISPR knockout of purine metabolic genes (e.g., ADA, HPRT1, IMPDH) in cell lines and animal models allows researchers to study loss-of-function phenotypes, such as altered nucleotide pools, growth defects, and disease-related pathologies. For example, ADA knockout in lymphocytes mimics SCID and can be used to test gene therapy approaches.
Point Mutation
Introducing disease-associated point mutations (e.g., in IMPDH1 or ADSL) via CRISPR base editing or HDR enables the study of specific enzymatic defects and their contribution to disorders like retinitis pigmentosa or adenylosuccinate lyase deficiency. These models are valuable for testing targeted therapies.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) or epitope tags into endogenous purine metabolic genes facilitates real-time monitoring of expression, localization, and interaction. Tagged knock-in models are also useful for drug screening and target engagement studies.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of purine metabolic enzymes (e.g., GART, IMPDH) can model enzyme upregulation observed in cancer. These models help dissect the oncogenic role of purine synthesis and evaluate inhibitors.
How EDITGENE Supports purine-containing compound metabolic process Research
Researchers studying purine-containing compound metabolic process-related genes often need to determine whether a candidate gene is causally involved in disease or metabolic regulation. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for purine-containing compound metabolic process research.
Frequently Asked Questions About purine-containing compound metabolic process
What is GO:0072521?
GO:0072521 is the Gene Ontology term for purine-containing compound metabolic process, which encompasses all chemical reactions and pathways involving purine-containing compounds such as nucleotides, nucleosides, and bases.
What genes are involved in purine-containing compound metabolic process?
Key genes include ADA, GART, IMPDH1/2, HPRT1, XDH, APRT, PNP, PFAS, PAICS, ADSL, ATIC, and many others encoding enzymes for synthesis, salvage, and degradation.
Why is purine metabolism important in cancer?
Cancer cells often upregulate de novo purine synthesis to support rapid proliferation. Enzymes like IMPDH and GART are overexpressed and are targets for chemotherapy.
What diseases are linked to purine metabolism defects?
Defects cause SCID (ADA deficiency), Lesch-Nyhan syndrome (HPRT1 deficiency), gout (XDH overactivity), and neurological disorders (ADSL deficiency).
How can CRISPR be used to study purine metabolism?
CRISPR knockout, knock-in, and point mutation models allow functional dissection of purine metabolic genes in cell lines and animals, revealing disease mechanisms and drug targets.
What are the main pathways in purine metabolism?
The main pathways are de novo biosynthesis, salvage pathways, interconversion of nucleotides, and catabolism to uric acid.
Which enzymes are targeted for gout treatment?
Xanthine dehydrogenase (XDH) is targeted by allopurinol to reduce uric acid production.
How does aging affect purine metabolism?
Proteomic and acetylome profiling studies have shown that purine metabolic enzymes undergo dynamic changes in expression and acetylation during aging.
What is the role of adenosine signaling in the brain?
Adenosine, a purine nucleoside, modulates neurotransmission via receptors like ADORA2A, and its dysregulation is implicated in Alzheimer's disease.
Can purine metabolism be studied with proteomics?
Yes, proteomics and acetylome profiling are powerful for quantifying purine metabolic enzymes and their post-translational modifications in tissues.
Conclusion
Purine-containing compound metabolic process (GO:0072521) is a fundamental biological pathway with far-reaching implications for human health and disease. From providing building blocks for nucleic acids to regulating immune responses and neuronal signaling, purine metabolism is a rich area of research. Advances in CRISPR gene editing, proteomics, and metabolomics are enabling unprecedented insights into this pathway, paving the way for novel therapeutics. EDITGENE is committed to supporting this research with state-of-the-art models and services.
References
- 1. Gao Y et al.. 2025. Discovery of Novel Antiepileptic Agents Targeting the α1β2γ2 GABA(A) Receptor.. J Med Chem 68(16):17971-17989 PMID: 40788257
- 2. Mohamed BS et al.. 2023. Purine containing carbonucleoside phosphonate analogues as novel chemotype for Plasmodium falciparum Inhibition.. Eur J Med Chem 258:115581 PMID: 37402342
- 3. Liu JF et al.. 2020. Global Lysine Crotonylation Profiling of Mouse Liver.. Proteomics 20(19-20):e2000049 PMID: 32864800
- 4. Danielewicz H et al.. 2021. Maternal atopy and offspring epigenome-wide methylation signature.. Epigenetics 16(6):629-641 PMID: 32902349
- 5. Liu G et al.. 2023. Comparative proteomics analysis of adult Haemonchus contortus isolates from Ovis ammon.. Front Cell Infect Microbiol 13:1087210 PMID: 37009511
- 6. Liu JF et al.. 2021. [Proteome and Acetylome Profiling of Livers in C57BL/6J Male Mice during Normal Aging].. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 43(5):696-705 PMID: 34728030
- 7. Oliveira-Lima OC et al.. 2024. GlyT1 Inhibition by NFPS Promotes Neuroprotection in Amyloid-β-Induced Alzheimer's Disease Animal Model.. Neurochem Res 49(9):2535-2555 PMID: 38888830
- 8. Mi S et al.. 2019. Characterization and discrimination of Tibetan and Duroc × (Landrace × Yorkshire) pork using label-free quantitative proteomics analysis.. Food Res Int 119:426-435 PMID: 30884673
